(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of 18% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Dynavax Technologies's revenue in 2025 is $277,246,000.On average, 2 Wall Street analysts forecast DVAX's revenue for 2025 to be $40,329,843,321, with the lowest DVAX revenue forecast at $39,794,477,693, and the highest DVAX revenue forecast at $40,865,208,948. On average, 2 Wall Street analysts forecast DVAX's revenue for 2026 to be $48,771,622,526, with the lowest DVAX revenue forecast at $47,201,506,185, and the highest DVAX revenue forecast at $50,341,738,867.
In 2027, DVAX is forecast to generate $56,376,543,989 in revenue, with the lowest revenue forecast at $52,604,790,788 and the highest revenue forecast at $60,148,297,191.